- $725.99m
- $674.90m
- $183.88m
Geron Corp expected to post a loss of 10 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Emeren Group, Steel Dynamics, NYCB
Geron surges as blood disorder drug gets FDA advisers' backing
U.S. STOCKS ON THE MOVE-Intuitive Surgical, NuScale Power, Hibbett
U.S. STOCKS ON THE MOVE-WW International, Madrigal, Micron Technology
Geron surges after blood disorder drug gets FDA advisers' backing
Geron's blood disorder drug gets FDA advisers' backing (updated)
Geron's blood disorder drug gets FDA advisers' backing
U.S. STOCKS ON THE MOVE-Rumble, Geron, Gold miners
U.S. STOCKS ON THE MOVE-Li-Cycle Holdings, Priority Technology, 3M
Geron falls after US FDA staff flags concerns on its blood disorder drug
US FDA staff flags concerns about Geron's anemia treatment (updated)
US FDA staff flags concerns about Geron's anemia treatment
Geron Corp reports results for the quarter ended in September - Earnings Summary
Brief: Geron Q4 EPS USD -0.09 Vs. IBES Estimate USD -0.1
Geron Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: Geron Corp Amends Existing Term Loan Facility With Silicon Valley Bank, Hercules Capital Inc
Brief: Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
Brief: Geron Announces Publication In The Lancet Of Results From The IMerge Phase 3 Clinical Trial Evaluating Imetelstat In Lower Risk MDS